BioDelivery Sciences International, Inc. (NASDAQ:BDSI) has been given a $5.00 target price by stock analysts at Roth Capital in a report issued on Tuesday, May 16th. The firm presently has a “buy” rating on the specialty pharmaceutical company’s stock. Roth Capital’s price objective indicates a potential upside of 117.39% from the company’s previous close.
Several other analysts have also issued reports on the stock. Zacks Investment Research lowered shares of BioDelivery Sciences International from a “hold” rating to a “sell” rating in a report on Tuesday, March 14th. FBR & Co set a $5.00 price target on shares of BioDelivery Sciences International and gave the stock a “buy” rating in a research note on Thursday, February 2nd. Cantor Fitzgerald set a $3.00 price target on shares of BioDelivery Sciences International and gave the stock a “hold” rating in a research note on Wednesday, March 22nd. Finally, Janney Montgomery Scott reiterated a “buy” rating and set a $3.00 price target on shares of BioDelivery Sciences International in a research note on Monday, March 20th. Three equities research analysts have rated the stock with a sell rating and five have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $3.71.
Shares of BioDelivery Sciences International (BDSI) remained flat at $2.30 during midday trading on Tuesday. The company’s stock had a trading volume of 309,349 shares. The firm’s market capitalization is $127.25 million. BioDelivery Sciences International has a 12 month low of $1.50 and a 12 month high of $3.10. The firm’s 50-day moving average is $2.13 and its 200 day moving average is $1.93.
BioDelivery Sciences International (NASDAQ:BDSI) last issued its quarterly earnings data on Monday, May 15th. The specialty pharmaceutical company reported $0.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.09 by $0.49. The firm had revenue of $29.48 million for the quarter, compared to analyst estimates of $27.07 million. BioDelivery Sciences International had a negative net margin of 0.19% and a negative return on equity of 1.45%. On average, equities analysts expect that BioDelivery Sciences International will post $0.13 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Roth Capital Analysts Give BioDelivery Sciences International, Inc. (BDSI) a $5.00 Price Target” was first reported by Markets Daily and is the property of of Markets Daily. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this piece of content can be read at https://www.themarketsdaily.com/2017/06/16/biodelivery-sciences-international-inc-bdsi-given-a-5-00-price-target-by-roth-capital-analysts-updated-updated-updated.html.
In related news, CEO Mark A. Sirgo sold 110,895 shares of the company’s stock in a transaction that occurred on Friday, March 31st. The shares were sold at an average price of $1.90, for a total transaction of $210,700.50. Following the sale, the chief executive officer now directly owns 1,670,157 shares in the company, valued at $3,173,298.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold 112,345 shares of company stock worth $213,456 over the last 90 days. Insiders own 9.00% of the company’s stock.
A number of institutional investors have recently made changes to their positions in the stock. Stonepine Capital Management LLC acquired a new position in shares of BioDelivery Sciences International during the fourth quarter worth about $4,551,000. GSA Capital Partners LLP acquired a new position in shares of BioDelivery Sciences International during the fourth quarter worth about $142,000. Searle & CO. increased its position in shares of BioDelivery Sciences International by 27.1% in the fourth quarter. Searle & CO. now owns 234,100 shares of the specialty pharmaceutical company’s stock worth $410,000 after buying an additional 49,850 shares during the period. Oxford Asset Management increased its position in shares of BioDelivery Sciences International by 280.8% in the fourth quarter. Oxford Asset Management now owns 107,945 shares of the specialty pharmaceutical company’s stock worth $189,000 after buying an additional 79,599 shares during the period. Finally, Baker BROS. Advisors LP acquired a new position in shares of BioDelivery Sciences International during the third quarter worth about $567,000. 40.32% of the stock is owned by hedge funds and other institutional investors.
About BioDelivery Sciences International
BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.
Receive News & Ratings for BioDelivery Sciences International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.